Product Name | Quizartinib (AC220) |
---|---|
CAS | 950769-58-1 |
Formula | C29H32N6O4S |
MW | 560.67 |
Appearance | White to off-white powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
5 mg | 3-5days | ¥450.00 | Visible after login | |
10 mg | 3-5days | ¥650.00 | Visible after login | |
25 mg | 3-5days | ¥950.00 | Visible after login |
Product Name | Quizartinib (AC220) |
---|---|
CAS | 950769-58-1 |
Formula | C29H32N6O4S |
MW | 560.67 |
Appearance | White to off-white powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Quizartinib (formerly also know as AC-220; AC-010220, Vanflyta) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.With IC50s of 1.1 nM and 4.2 nM, respectively, it inhibits FLT3 in MV4-11 and RS4EL11 cells. With respect to KIT, PDGFRα, PDGFRβ, RET, and CSF-1R, it demonstrates a ten-fold greater selectivity. Currently, Daiichi Sankyo is developing quizartinib to treat acute myeloid leukemia. Quizartinib (Vanflyta) was approved in 2023 by FDA for treating AML.